Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 89 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Shionogi Inc. Clear all
Completed Phase 1 Interventional

A Phase 1 Study of S-3304 in Patients With Solid Tumors

NCT00033215
View directory record Official record
Conditions
Solid Tumors
Interventions
S-3304
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
4
States / cities
Denver, Colorado • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 31, 2026, 8:21 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

NCT04569084
View directory record Official record
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
34
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy

NCT01240759
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
S-707106 Dose A, S-707106 Dose B, S-707106 Dose C, Placebo A tablet, Metformin
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional

Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy

NCT05373615
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Cefiderocol
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

NCT05953480
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Redasemtide, Placebo
Biological · Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of S-309309 in Obese Adults

NCT05925114
View directory record Official record
Conditions
Obesity
Interventions
S-309309, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of BPN14770 on Rosuvastatin

NCT07011992
View directory record Official record
Conditions
Healthy Participants
Interventions
Rosuvastatin, BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

NCT06775730
View directory record Official record
Conditions
Healthy Adult Female Participants
Interventions
Ensitrelvir
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911
View directory record Official record
Conditions
Hepatic Impairment
Interventions
S-217622
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

NCT00556478
View directory record Official record
Conditions
Premature Ejaculation
Interventions
PSD502, contains a mixture of lidocaine and prilocaine, Placebo
Drug
Lead sponsor
Plethora Solutions Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 31, 2026, 8:21 AM EDT
Completed No phase listed Observational

A Study to Investigate How Respiratory Syncytial Virus (RSV) Infection Develops and Changes Over Time in Pediatric Participants

NCT06746051
View directory record Official record
Conditions
RSV Infections
Interventions
Not listed
Lead sponsor
Shionogi
Industry
Eligibility
Up to 36 Months
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Syracuse, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 31, 2026, 8:21 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)

NCT01054443
View directory record Official record
Conditions
Immune Thrombocytopenia (ITP)
Interventions
Placebo, Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

Double-Blind, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Velneperit (S-2367) and Orlistat Administered Individually or Combined With a Reduced Calorie Diet (RCD) in Obese Subjects

NCT01126970
View directory record Official record
Conditions
Obesity
Interventions
Velneperit 400 mg, Orlistat 120 mg, Orlistat Placebo, Velneperit Placebo, Reduced Calorie Diet
Drug · Other
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Santa Rosa, California • Waterbury, Connecticut • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 31, 2026, 8:21 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 31, 2026, 8:21 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

NCT05151471
View directory record Official record
Conditions
ALS
Interventions
MT-1186, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Rogers, Arkansas • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

NCT06717438
View directory record Official record
Conditions
Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
9 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls

NCT07012005
View directory record Official record
Conditions
Renal Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

NCT02106585
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-251 or Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 31, 2026, 8:21 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea

NCT06776432
View directory record Official record
Conditions
Sleep Apnea
Interventions
Sivopixant, Placebo, Acetazolamide, SASS-001
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
La Jolla, California • Brandon, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls

NCT07018492
View directory record Official record
Conditions
Hepatic Impairment
Interventions
BPN14770
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 8:21 AM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic Dermatitis

NCT00703573
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S-777469 400 mg, S-777469 800 mg, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
33
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 31, 2026, 8:21 AM EDT